JP2008535871A - 器官又は組織における線維症を処置するための医薬の製造における５−メチル−１−（置換されたフェニル）−２−（１ｈ）−ピリドン - Google Patents
器官又は組織における線維症を処置するための医薬の製造における５−メチル−１−（置換されたフェニル）−２−（１ｈ）−ピリドン Download PDFInfo
- Publication number
- JP2008535871A JP2008535871A JP2008505716A JP2008505716A JP2008535871A JP 2008535871 A JP2008535871 A JP 2008535871A JP 2008505716 A JP2008505716 A JP 2008505716A JP 2008505716 A JP2008505716 A JP 2008505716A JP 2008535871 A JP2008535871 A JP 2008535871A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridone
- fibrosis
- compound
- akf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 29
- 230000004761 fibrosis Effects 0.000 title claims abstract description 29
- -1 5-Methyl-1- (substituted phenyl) -2- (1H) -pyridone Chemical class 0.000 title claims abstract description 27
- 210000000056 organ Anatomy 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- JDZYVVUJIQYGRX-UHFFFAOYSA-N 1-(3-fluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(F)=C1 JDZYVVUJIQYGRX-UHFFFAOYSA-N 0.000 claims description 109
- 229940079593 drug Drugs 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 230000003176 fibrotic effect Effects 0.000 claims description 7
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 5
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical group O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 5
- 201000004409 schistosomiasis Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- IFCIIDXNZSQOPD-UHFFFAOYSA-N 1-(2,3-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(Br)=C1Br IFCIIDXNZSQOPD-UHFFFAOYSA-N 0.000 claims description 2
- XYPVXRNOJDTEDJ-UHFFFAOYSA-N 1-(2,3-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(Cl)=C1Cl XYPVXRNOJDTEDJ-UHFFFAOYSA-N 0.000 claims description 2
- MIUCEBJFPNOZFC-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(F)=C1F MIUCEBJFPNOZFC-UHFFFAOYSA-N 0.000 claims description 2
- DIVMPFRJHNDQHW-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(Cl)C=C1Cl DIVMPFRJHNDQHW-UHFFFAOYSA-N 0.000 claims description 2
- ICETYRMEWRWSJX-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(F)C=C1F ICETYRMEWRWSJX-UHFFFAOYSA-N 0.000 claims description 2
- IXSFWFDBKAFHHA-UHFFFAOYSA-N 1-(2,5-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(Br)=CC=C1Br IXSFWFDBKAFHHA-UHFFFAOYSA-N 0.000 claims description 2
- MDXCTWOGPDQWFR-UHFFFAOYSA-N 1-(2,5-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(F)=CC=C1F MDXCTWOGPDQWFR-UHFFFAOYSA-N 0.000 claims description 2
- ZEICHSKCYQRIIG-UHFFFAOYSA-N 1-(2,6-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(Br)C=CC=C1Br ZEICHSKCYQRIIG-UHFFFAOYSA-N 0.000 claims description 2
- DMZNWOKZNPSKSP-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(Cl)C=CC=C1Cl DMZNWOKZNPSKSP-UHFFFAOYSA-N 0.000 claims description 2
- CXIJPJZPSZHTNT-UHFFFAOYSA-N 1-(2,6-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(F)C=CC=C1F CXIJPJZPSZHTNT-UHFFFAOYSA-N 0.000 claims description 2
- QLFMOQVBGPZBAY-UHFFFAOYSA-N 1-(2-bromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1Br QLFMOQVBGPZBAY-UHFFFAOYSA-N 0.000 claims description 2
- LNCCSHHBXXNHHJ-UHFFFAOYSA-N 1-(2-fluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1F LNCCSHHBXXNHHJ-UHFFFAOYSA-N 0.000 claims description 2
- DCDSWTUVNHBRJZ-UHFFFAOYSA-N 1-(2-iodophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1I DCDSWTUVNHBRJZ-UHFFFAOYSA-N 0.000 claims description 2
- PPEKVFBDIFWVEV-UHFFFAOYSA-N 1-(3,4-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(Br)C(Br)=C1 PPEKVFBDIFWVEV-UHFFFAOYSA-N 0.000 claims description 2
- NUFQXKSYNQFJSW-UHFFFAOYSA-N 1-(3,5-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(Br)=CC(Br)=C1 NUFQXKSYNQFJSW-UHFFFAOYSA-N 0.000 claims description 2
- RMHNSSKWHOINQA-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(Cl)=CC(Cl)=C1 RMHNSSKWHOINQA-UHFFFAOYSA-N 0.000 claims description 2
- SGVKQHZMSAOGLV-UHFFFAOYSA-N 1-(3,5-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(F)=CC(F)=C1 SGVKQHZMSAOGLV-UHFFFAOYSA-N 0.000 claims description 2
- PYZJZGLJFOVHRH-UHFFFAOYSA-N 1-(4-bromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(Br)C=C1 PYZJZGLJFOVHRH-UHFFFAOYSA-N 0.000 claims description 2
- NNOLFDHGQTWVGS-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(F)C=C1 NNOLFDHGQTWVGS-UHFFFAOYSA-N 0.000 claims description 2
- HUSOSDHHWHLZRF-UHFFFAOYSA-N 1-(4-iodophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(I)C=C1 HUSOSDHHWHLZRF-UHFFFAOYSA-N 0.000 claims description 2
- CPJBLJUDFSFZEP-UHFFFAOYSA-N 1-[2,3-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(C(F)(F)F)=C1C(F)(F)F CPJBLJUDFSFZEP-UHFFFAOYSA-N 0.000 claims description 2
- WMCCIACZTXJBNZ-UHFFFAOYSA-N 1-[2,4-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(C(F)(F)F)C=C1C(F)(F)F WMCCIACZTXJBNZ-UHFFFAOYSA-N 0.000 claims description 2
- NCNYJVDWMNCSPR-UHFFFAOYSA-N 1-[2,5-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(C(F)(F)F)=CC=C1C(F)(F)F NCNYJVDWMNCSPR-UHFFFAOYSA-N 0.000 claims description 2
- QQOSQRFHCXTCMT-UHFFFAOYSA-N 1-[2,6-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(C(F)(F)F)C=CC=C1C(F)(F)F QQOSQRFHCXTCMT-UHFFFAOYSA-N 0.000 claims description 2
- LZWXKBBDHOJVPZ-UHFFFAOYSA-N 1-[3,4-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(C(F)(F)F)C(C(F)(F)F)=C1 LZWXKBBDHOJVPZ-UHFFFAOYSA-N 0.000 claims description 2
- RRHMWKBGPCGEOI-UHFFFAOYSA-N 5-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1C(F)(F)F RRHMWKBGPCGEOI-UHFFFAOYSA-N 0.000 claims description 2
- IKTCWTVJVXLKRU-UHFFFAOYSA-N 5-methyl-1-[4-(trifluoromethyl)phenyl]pyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(C(F)(F)F)C=C1 IKTCWTVJVXLKRU-UHFFFAOYSA-N 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- BMLCFMLMGNOAPP-UHFFFAOYSA-N 1-(2,3-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=CC(N2C(C=CC(C)=C2)=O)=C1OC BMLCFMLMGNOAPP-UHFFFAOYSA-N 0.000 claims 1
- JFBQYHYEBRHAPT-UHFFFAOYSA-N 1-(2,3-dimethylphenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(C)=C1C JFBQYHYEBRHAPT-UHFFFAOYSA-N 0.000 claims 1
- PQEYQPAPGLIVEI-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)-5-methylpyridin-2-one Chemical compound CC1=CC(C)=CC=C1N1C(=O)C=CC(C)=C1 PQEYQPAPGLIVEI-UHFFFAOYSA-N 0.000 claims 1
- IFJQAFSORYKHGW-UHFFFAOYSA-N 1-(2,5-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=C(OC)C(N2C(C=CC(C)=C2)=O)=C1 IFJQAFSORYKHGW-UHFFFAOYSA-N 0.000 claims 1
- LVXOEVCZHWSZMZ-UHFFFAOYSA-N 1-(2,5-dimethylphenyl)-5-methylpyridin-2-one Chemical compound CC1=CC=C(C)C(N2C(C=CC(C)=C2)=O)=C1 LVXOEVCZHWSZMZ-UHFFFAOYSA-N 0.000 claims 1
- PIZBPTZVIPMEJT-UHFFFAOYSA-N 1-(2,6-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=CC(OC)=C1N1C(=O)C=CC(C)=C1 PIZBPTZVIPMEJT-UHFFFAOYSA-N 0.000 claims 1
- BHBNMKITFOZDAB-UHFFFAOYSA-N 1-(2,6-dimethylphenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(C)C=CC=C1C BHBNMKITFOZDAB-UHFFFAOYSA-N 0.000 claims 1
- MJWRQZILSOKOTB-UHFFFAOYSA-N 1-(2-methoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=CC=C1N1C(=O)C=CC(C)=C1 MJWRQZILSOKOTB-UHFFFAOYSA-N 0.000 claims 1
- GAHWJIZKEGFRLL-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)C=CC(C)=C1 GAHWJIZKEGFRLL-UHFFFAOYSA-N 0.000 claims 1
- KXSZGLHSEASUBA-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(C)C(C)=C1 KXSZGLHSEASUBA-UHFFFAOYSA-N 0.000 claims 1
- CEKMQLXFPZYWRU-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC(OC)=CC(N2C(C=CC(C)=C2)=O)=C1 CEKMQLXFPZYWRU-UHFFFAOYSA-N 0.000 claims 1
- DLAIQUGBQRXOBE-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(C)=CC(C)=C1 DLAIQUGBQRXOBE-UHFFFAOYSA-N 0.000 claims 1
- MCAAQJLJBILPBZ-UHFFFAOYSA-N 1-(3-bromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(Br)=C1 MCAAQJLJBILPBZ-UHFFFAOYSA-N 0.000 claims 1
- QOXOVUCNQVZUEH-UHFFFAOYSA-N 1-(3-iodophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(I)=C1 QOXOVUCNQVZUEH-UHFFFAOYSA-N 0.000 claims 1
- NUUFOILDYXVXLL-UHFFFAOYSA-N 1-(3-methoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=CC(N2C(C=CC(C)=C2)=O)=C1 NUUFOILDYXVXLL-UHFFFAOYSA-N 0.000 claims 1
- VYXSRCVSKXRDAN-UHFFFAOYSA-N 5-methyl-1-(2-methylphenyl)pyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1C VYXSRCVSKXRDAN-UHFFFAOYSA-N 0.000 claims 1
- NDGCMBKTLPWHDG-UHFFFAOYSA-N 5-methyl-1-(3-methylphenyl)pyridin-2-one Chemical compound CC1=CC=CC(N2C(C=CC(C)=C2)=O)=C1 NDGCMBKTLPWHDG-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 abstract description 62
- 229960003073 pirfenidone Drugs 0.000 abstract description 60
- 230000000694 effects Effects 0.000 abstract description 16
- 230000003510 anti-fibrotic effect Effects 0.000 abstract description 13
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 29
- 241000700159 Rattus Species 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 22
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000012679 serum free medium Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 230000001434 glomerular Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 241000242678 Schistosoma Species 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010061435 Enalapril Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 4
- 229960000873 enalapril Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 208000009928 nephrosis Diseases 0.000 description 4
- 231100001027 nephrosis Toxicity 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 108010006654 Bleomycin Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 229940044627 gamma-interferon Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- LUYVIZYIGZWLEK-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(Cl)=CC=C1Cl LUYVIZYIGZWLEK-UHFFFAOYSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039610 Schistosomiasis liver Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100314457A CN1846699A (zh) | 2005-04-13 | 2005-04-13 | 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
| PCT/CN2006/000651 WO2006108354A1 (fr) | 2005-04-13 | 2006-04-11 | 5-méthyl-2-(1h)-pyridone substituée en 1 par un groupement phényle dans la fabrication de médicaments pour le traitement de la fibrose d'organes ou de tissus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535871A true JP2008535871A (ja) | 2008-09-04 |
| JP2008535871A5 JP2008535871A5 (enExample) | 2009-06-18 |
Family
ID=37076581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505716A Pending JP2008535871A (ja) | 2005-04-13 | 2006-04-11 | 器官又は組織における線維症を処置するための医薬の製造における５−メチル−１−（置換されたフェニル）−２−（１ｈ）−ピリドン |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20090005424A9 (enExample) |
| EP (1) | EP1878428A4 (enExample) |
| JP (1) | JP2008535871A (enExample) |
| KR (1) | KR20080018857A (enExample) |
| CN (2) | CN1846699A (enExample) |
| AU (1) | AU2006233433A1 (enExample) |
| CA (1) | CA2603763A1 (enExample) |
| RU (1) | RU2007141892A (enExample) |
| TW (1) | TW200808315A (enExample) |
| WO (1) | WO2006108354A1 (enExample) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8725326B2 (en) | 2006-03-20 | 2014-05-13 | General Electric Company | System and method for predicting a vehicle route using a route network database |
| US8751073B2 (en) | 2006-03-20 | 2014-06-10 | General Electric Company | Method and apparatus for optimizing a train trip using signal information |
| US8903573B2 (en) | 2006-03-20 | 2014-12-02 | General Electric Company | Method and computer software code for determining a mission plan for a powered system when a desired mission parameter appears unobtainable |
| US8924049B2 (en) | 2003-01-06 | 2014-12-30 | General Electric Company | System and method for controlling movement of vehicles |
| US9156477B2 (en) | 2006-03-20 | 2015-10-13 | General Electric Company | Control system and method for remotely isolating powered units in a vehicle system |
| JP2016540800A (ja) * | 2013-12-19 | 2016-12-28 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 窒素複素環誘導体およびその医薬品への応用 |
| US9669851B2 (en) | 2012-11-21 | 2017-06-06 | General Electric Company | Route examination system and method |
| US9733625B2 (en) | 2006-03-20 | 2017-08-15 | General Electric Company | Trip optimization system and method for a train |
| US9834237B2 (en) | 2012-11-21 | 2017-12-05 | General Electric Company | Route examining system and method |
| US10308265B2 (en) | 2006-03-20 | 2019-06-04 | Ge Global Sourcing Llc | Vehicle control system and method |
| US10569792B2 (en) | 2006-03-20 | 2020-02-25 | General Electric Company | Vehicle control system and method |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047256A1 (en) | 2003-11-14 | 2005-05-26 | Shanghai Genomics, Inc. | The derivatives of pyridone and the use of them |
| CN1846699A (zh) * | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
| BRPI0608907A2 (pt) | 2005-05-10 | 2010-02-17 | Itermune Inc | método de modulação de sistema de proteìna cinase ativada por estresse |
| US9689681B2 (en) | 2014-08-12 | 2017-06-27 | General Electric Company | System and method for vehicle operation |
| WO2009039773A1 (fr) * | 2007-09-19 | 2009-04-02 | Central South University | Nouvelle utilisation thérapeutique d'une aryl-2(1h)-pyridone substituée en position 1 |
| CN101235013A (zh) * | 2008-03-10 | 2008-08-06 | 广东东阳光药业有限公司 | 结晶型1-（3-氟苯基）-5-甲基-2-（1h）吡啶酮、其制备方法、及其组合物和应用 |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| CN101918364B (zh) * | 2008-10-21 | 2013-02-13 | 史跃年 | 用于治疗高蛋白尿的药物组合物 |
| US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
| US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| US8016980B2 (en) | 2008-11-25 | 2011-09-13 | Dixie Consumer Products Llc | Paper products |
| CN101921225B (zh) * | 2009-06-11 | 2013-04-03 | 北京凯得尔森生物技术有限公司 | 吡啡尼酮类化合物、其制备方法和应用 |
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| US8084475B2 (en) * | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
| US10092552B2 (en) | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| EP2875001B1 (en) * | 2012-07-18 | 2019-01-09 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
| CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9682716B2 (en) | 2012-11-21 | 2017-06-20 | General Electric Company | Route examining system and method |
| EP4491180A1 (en) | 2014-01-10 | 2025-01-15 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2942384C (en) | 2014-03-12 | 2024-01-23 | Icahn School Of Medicine At Mount Sinai | Method for identifying kidney allograft recipients at risk for chronic injury |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| CN106661635B (zh) | 2014-06-26 | 2021-05-28 | 西奈山伊坎医学院 | 通过分析预示性基因集诊断亚临床和临床的急性排异的方法 |
| US20170266168A1 (en) * | 2014-09-18 | 2017-09-21 | Rush University Medical Center | Methods for preventing or treating osteoarthritis |
| DE102015217418A1 (de) | 2015-09-11 | 2017-03-16 | Mühlbauer Technology Gmbh | Radikalisch polymerisierbares Dentalmaterial |
| EP3308765B1 (de) | 2016-10-17 | 2022-07-13 | Mühlbauer Technology GmbH | Radikalisch polymerisierbare verbindung |
| JP7393325B2 (ja) * | 2017-07-14 | 2023-12-06 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | ピリミドン化合物を調製するための方法 |
| AU2019255206B2 (en) | 2018-04-16 | 2024-08-01 | Icahn School Of Medicine At Mount Sinai | Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood |
| CN113456636A (zh) * | 2021-07-09 | 2021-10-01 | 中南大学 | 一种氟非尼酮在制备急性肝损伤药物中的应用 |
| CN113274389B (zh) * | 2021-07-09 | 2022-11-08 | 中南大学 | 氟非尼酮在制备治疗急性肺损伤药物中的应用 |
| CN114716365B (zh) * | 2022-01-04 | 2024-03-01 | 大连理工大学 | 一类n-取代苯基-2-吡啶酮化合物或其可药用盐在治疗肺纤维化中的应用 |
| WO2024235145A1 (zh) * | 2023-05-12 | 2024-11-21 | 大连理工大学 | 一类n-取代苯基-2-吡啶酮及内过氧化物的制备和应用 |
| CN118526493A (zh) * | 2023-10-30 | 2024-08-23 | 大连理工大学 | 一类n-取代苯基-2-吡啶酮化合物在治疗癌症和缓解纤维化中的应用 |
| CN120053452B (zh) * | 2023-11-30 | 2025-12-05 | 长沙晶易医药科技股份有限公司 | 一种2,4-二取代-5-氟嘧啶衍生物的新用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000051467A (ja) * | 1998-08-07 | 2000-02-22 | Takao:Kk | 弾球遊技機 |
| EP1138329A2 (en) * | 1989-02-15 | 2001-10-04 | Yamauchi, Shitotomo | Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
| CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
| US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
| US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| CN2114190U (zh) | 1992-01-09 | 1992-08-26 | 王刚 | 恒流一体化集成电源器件 |
| US5716623A (en) * | 1994-12-07 | 1998-02-10 | Immunex Corporation | Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules |
| CN1218942C (zh) * | 2002-06-11 | 2005-09-14 | 中南大学湘雅医学院 | 抗纤维化吡啶酮化合物及其生产工艺方法 |
| CN1846699A (zh) * | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
-
2005
- 2005-04-13 CN CNA2005100314457A patent/CN1846699A/zh active Pending
-
2006
- 2006-04-11 CN CN2006800002161A patent/CN1953749B/zh active Active
- 2006-04-11 KR KR1020077018590A patent/KR20080018857A/ko not_active Ceased
- 2006-04-11 AU AU2006233433A patent/AU2006233433A1/en not_active Abandoned
- 2006-04-11 CA CA002603763A patent/CA2603763A1/en not_active Abandoned
- 2006-04-11 RU RU2007141892/15A patent/RU2007141892A/ru not_active Application Discontinuation
- 2006-04-11 JP JP2008505716A patent/JP2008535871A/ja active Pending
- 2006-04-11 WO PCT/CN2006/000651 patent/WO2006108354A1/zh not_active Ceased
- 2006-04-11 EP EP06722303A patent/EP1878428A4/en not_active Withdrawn
- 2006-08-04 TW TW095128659A patent/TW200808315A/zh unknown
-
2007
- 2007-05-01 US US11/742,664 patent/US20090005424A9/en not_active Abandoned
-
2008
- 2008-09-04 US US12/204,629 patent/US20080319027A1/en not_active Abandoned
-
2009
- 2009-06-25 US US12/491,506 patent/US20090258911A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1138329A2 (en) * | 1989-02-15 | 2001-10-04 | Yamauchi, Shitotomo | Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions |
| JP2000051467A (ja) * | 1998-08-07 | 2000-02-22 | Takao:Kk | 弾球遊技機 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6012014338; Ｊ．Ｃｅｎｔ． Ｓｏｕｔｈ Ｕｎｉ． （Ｍｅｄ．Ｓｃｉ．） Ｖｏｌ．２９，Ｎｏ．２, 2004 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8924049B2 (en) | 2003-01-06 | 2014-12-30 | General Electric Company | System and method for controlling movement of vehicles |
| US8725326B2 (en) | 2006-03-20 | 2014-05-13 | General Electric Company | System and method for predicting a vehicle route using a route network database |
| US8751073B2 (en) | 2006-03-20 | 2014-06-10 | General Electric Company | Method and apparatus for optimizing a train trip using signal information |
| US8903573B2 (en) | 2006-03-20 | 2014-12-02 | General Electric Company | Method and computer software code for determining a mission plan for a powered system when a desired mission parameter appears unobtainable |
| US9156477B2 (en) | 2006-03-20 | 2015-10-13 | General Electric Company | Control system and method for remotely isolating powered units in a vehicle system |
| US9733625B2 (en) | 2006-03-20 | 2017-08-15 | General Electric Company | Trip optimization system and method for a train |
| US10308265B2 (en) | 2006-03-20 | 2019-06-04 | Ge Global Sourcing Llc | Vehicle control system and method |
| US10569792B2 (en) | 2006-03-20 | 2020-02-25 | General Electric Company | Vehicle control system and method |
| US9669851B2 (en) | 2012-11-21 | 2017-06-06 | General Electric Company | Route examination system and method |
| US9834237B2 (en) | 2012-11-21 | 2017-12-05 | General Electric Company | Route examining system and method |
| JP2016540800A (ja) * | 2013-12-19 | 2016-12-28 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 窒素複素環誘導体およびその医薬品への応用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1878428A1 (en) | 2008-01-16 |
| US20080319027A1 (en) | 2008-12-25 |
| EP1878428A4 (en) | 2008-09-03 |
| KR20080018857A (ko) | 2008-02-28 |
| CN1953749A (zh) | 2007-04-25 |
| WO2006108354A1 (fr) | 2006-10-19 |
| US20090005424A9 (en) | 2009-01-01 |
| CN1846699A (zh) | 2006-10-18 |
| US20090258911A1 (en) | 2009-10-15 |
| TW200808315A (en) | 2008-02-16 |
| RU2007141892A (ru) | 2009-05-20 |
| AU2006233433A1 (en) | 2006-10-19 |
| CA2603763A1 (en) | 2006-10-19 |
| US20070203203A1 (en) | 2007-08-30 |
| CN1953749B (zh) | 2010-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535871A (ja) | 器官又は組織における線維症を処置するための医薬の製造における５−メチル−１−（置換されたフェニル）−２−（１ｈ）−ピリドン | |
| RU2557243C2 (ru) | Фармацевтическая композиция, содержащая индольное соединение | |
| EP1364659A1 (en) | Remedies for urinary diseases comprising lpa receptor controlling agents | |
| JP7457360B2 (ja) | 線維症の処置 | |
| KR20080027191A (ko) | 신규한 벤즈옥사졸 유도체, 이의 제조방법 및 이를포함하는 약학 조성물 | |
| AU2022404695B2 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| Shao et al. | Stachydrine ameliorates the progression of intervertebral disc degeneration via the PI3K/Akt/NF-κB signaling pathway: in vitro and in vivo studies | |
| TW201026684A (en) | Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy | |
| ZA200407182B (en) | Dexanabinol and dexanabinol analogs regulate inflammation releated genes. | |
| JPH07500811A (ja) | アミノ置換ピリミジン、その誘導体及びその使用方法 | |
| TWI769325B (zh) | 糖尿病性腎病之預防藥及／或治療藥 | |
| JP2004534760A (ja) | 腎線維症の治療 | |
| TWI885807B (zh) | 一類具有萘胺結構的小分子化合物的用途 | |
| JP2022504184A (ja) | ブドウ膜黒色腫の治療のための併用療法 | |
| JP2008514636A (ja) | サイトカイン活性の低分子モジュレーター | |
| CN106466318A (zh) | 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用 | |
| WO2017216579A1 (en) | Autophagy inducer compounds | |
| KR102676631B1 (ko) | 과민성 방광의 예방 또는 치료용 약학적 조성물 | |
| EP4252751B1 (en) | Pharmaceutical composition for preventing or treating wound or scar, comprising benzbromarone | |
| JPH07145129A (ja) | β−ナフトキノン誘導体及びそれらの塩類の新規な用途 | |
| US20080287509A1 (en) | Pharmaceutical Composition for the Treatment of Bone Fracture | |
| WO2004094446A1 (ja) | １４員環マクロライド化合物を利用した、血管平滑筋の増殖に起因する疾患治療剤 | |
| CN120168445A (zh) | 化合物aj-091在制备系统性硬化症治疗药物中的应用 | |
| JP2025532992A (ja) | エナボグリフロジンを含む心血管老化疾患の予防又は治療用薬学組成物｛ｐｈａｒｍａｃｅｕｔｉｃａｌ ｃｏｍｐｏｓｉｔｉｏｎ ｆｏｒ ｐｒｅｖｅｎｔｉｎｇ ｏｒ ｔｒｅａｔｉｎｇ ｃａｒｄｉｏｖａｓｃｕｌａｒ ａｇｉｎｇ ｄｉｓｅａｓｅｓ ｃｏｎｔａｉｎｉｎｇ ｅｎａｖｏｇｌｉｆｌｏｚｉｎ｝ | |
| CN120682118A (zh) | 一种化合物msb-2o及其制备方法和应用与预防或治疗弓形虫感染药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090402 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090402 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120321 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120621 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120628 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120723 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120730 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120820 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120827 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130115 |